Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

03-16 -

More about the company

Quotes

Date	Price	Change	Volume
13/02/26	121.41 $	+1.82%	10,102,324
12/02/26	119.24 $	-0.06%	13,453,271
11/02/26	119.31 $	+1.84%	10,885,294
10/02/26	117.15 $	-0.42%	11,849,545
09/02/26	117.65 $	-3.51%	16,158,727

Delayed Quote Nyse

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Merck to Buy Verona Pharma for About $10B

July 09, 2025 at 07:30 pm

More analyses

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

121.41USD

Average target price

124.88USD

Spread / Average Target

+2.86%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 00:00:02 14/02/2026 +03			5-day change	1st Jan Change
121.41 ^USD	+1.82%		-0.43%	+15.34%

02-13	Merck Shares Rise After Deutsche Bank Upgrade	MT
02-13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT

Capitalization	301B 254B 232B 221B 410B 27,293B 426B 2,694B 1,069B 13,180B 1,130B 1,107B 46,066B	P/E ratio 2025	14.5x	P/E ratio 2026 *	27.9x
Enterprise value	326B 274B 250B 239B 444B 29,498B 461B 2,911B 1,156B 14,245B 1,221B 1,196B 49,787B	EV / Sales 2025	4.02x	EV / Sales 2026 *	4.93x
Free-Float	70.67%	Yield 2025 *	2.66%	Yield 2026 *	2.77%

02-13	Merck Shares Rise After Deutsche Bank Upgrade	MT
02-13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT
02-13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
02-13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
02-13	Merck & Co. Insider Sold Shares Worth $1,214,562, According to a Recent SEC Filing	MT
02-12	Argus Adjusts Price Target on Merck to $130 From $110, Maintains Buy Rating	MT
02-12	Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium	CI
02-11	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-11	Sector Update: Health Care Stocks Advance Wednesday Afternoon	MT
02-11	Sector Update: Health Care	MT
02-11	Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating	MT
02-11	Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX	CI
02-11	Agilent's Ovarian Cancer Diagnostic Test Receives FDA Clearance	MT

02-13	Merck Shares Rise After Deutsche Bank Upgrade	MT
02-13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
02-13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
02-12	Argus Adjusts Price Target on Merck to $130 From $110, Maintains Buy Rating	MT
02-11	Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating	MT

Merck & Co., Inc. Stock

Equities

MRK

US58933Y1055

Pharmaceuticals

Valuation: Merck & Co., Inc.

Chart: Merck & Co., Inc.

Latest news: Merck & Co., Inc.

Last Transcript: Merck & Co., Inc.

Analysts' recommendations: Merck & Co., Inc.

Press Releases: Merck & Co., Inc.

News in other languages: Merck & Co., Inc.

Trading Merck & Co., Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Merck & Co., Inc.

ETFs: Merck & Co., Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-12	Merck - KEYTRUDA and KEYTRUDA QLEX, Plus Paclitaxel +/- Bevacizumab, Approved for Certain Adults with PD-L1+ Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment	AQ
02-12	Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	AQ
02-12	Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium	BU
02-11	KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment	BU
02-05	Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants	AQ

02-11	Goldlöckchen-Arbeitsmarkt - nervöse Märkte
02-06	Günstigere Medikamente? Trump startet neues Regierungsportal
02-06	USA-Trump dévoile TrumpRx, un site d'achats en ligne de médicaments à prix réduits
02-04	MÄRKTE USA/Wirbel im KI-Sektor belastet Wall Street
02-03	MÄRKTE USA/Wall Street dreht klar ins Minus - Wirbel im KI-Sektor

1 day	+1.82%
1 week	-0.43%
Current month	+10.10%
1 month	+9.37%
3 months	+30.66%
6 months	+46.70%
Current year	+15.34%

1 week	116.1	123.33
1 month	106.03	123.33
Current year	104.43	123.33
1 year	73.31	123.33
3 years	73.31	134.63
5 years	70.89	134.63
10 years	49.24	134.63

Manager	Title	Age	Since
Robert Davis CEO	Chief Executive Officer	59	01/07/2021
Caroline Litchfield DFI	Director of Finance/CFO	57	01/04/2021
Dave Williams CTO	Chief Tech/Sci/R&D Officer	57	01/08/2020

Director	Title	Age	Since
Tom Glocer BRD	Director/Board Member	65	27/11/2007
Patricia Russo BRD	Director/Board Member	73	01/09/1995
Robert Davis CHM	Chairman	59	01/12/2022

Name		Varia. Jan 1.	Weight	AuM
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD		-2.15%	14.34%	253 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY		-0.48%	5.61%	26 M€

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MERCK & CO., INC.	+1.82%	-0.43%	+46.26%	+11.65%	301B
ELI LILLY AND COMPANY	+0.33%	-1.72%	+23.18%	+199.23%	929B
JOHNSON & JOHNSON	-0.45%	+1.44%	+55.91%	+50.24%	587B
ABBVIE INC.	+1.76%	+3.61%	+20.03%	+51.71%	409B
ROCHE HOLDING AG	+0.08%	+1.01%	+20.89%	+28.94%	374B
ASTRAZENECA PLC	+1.42%	+7.19%	+26.36%	+32.36%	320B
NOVARTIS AG	+1.08%	+4.32%	+27.98%	+55.61%	311B
NOVO NORDISK A/S	+1.32%	+5.11%	-45.12%	-37.51%	219B
AMGEN INC.	+1.52%	-3.94%	+26.80%	+53.17%	199B
GILEAD SCIENCES, INC.	+2.09%	+1.63%	+48.90%	+80.88%	192B
Average	+1.10%	+1.96%	+25.12%	+52.63%	384.1B
Weighted average by Cap.	+0.81%	+1.58%	+27.66%	+76.96%

	2025	2026 *
Net sales	64.78B 54.58B 49.78B 47.53B 88.23B 5,867B 91.67B 579B 230B 2,833B 243B 238B 9,903B	66.71B 56.21B 51.27B 48.94B 90.86B 6,042B 94.4B 596B 237B 2,918B 250B 245B 10,198B
Net income	19.82B 16.7B 15.23B 14.54B 26.99B 1,795B 28.04B 177B 70.32B 867B 74.31B 72.78B 3,029B	10.76B 9.06B 8.27B 7.89B 14.65B 974B 15.22B 96.16B 38.17B 471B 40.34B 39.51B 1,644B
Net Debt	24.34B 20.51B 18.71B 17.86B 33.15B 2,205B 34.44B 218B 86.38B 1,065B 91.28B 89.41B 3,721B	27.63B 23.28B 21.24B 20.27B 37.63B 2,503B 39.1B 247B 98.05B 1,209B 104B 101B 4,224B